SI-BONE (SIBN) Stock Overview
A medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SIBN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SI-BONE, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.79 |
| 52 Week High | US$20.05 |
| 52 Week Low | US$11.70 |
| Beta | 0.84 |
| 1 Month Change | 12.38% |
| 3 Month Change | -11.29% |
| 1 Year Change | 20.44% |
| 3 Year Change | -15.47% |
| 5 Year Change | -27.03% |
| Change since IPO | -21.29% |
Recent News & Updates
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Jun 26
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
May 09Recent updates
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Jun 26Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
May 09Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
May 08SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
Mar 27
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
Jan 19Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
Nov 04Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Sep 25SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
Apr 01Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
Feb 29Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Feb 28Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Nov 12Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Aug 09Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Apr 20Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Jan 01Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Sep 24SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
Apr 19Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Jan 05Shareholder Returns
| SIBN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.7% | 1.7% | 2.1% |
| 1Y | 20.4% | 2.2% | 18.7% |
Return vs Industry: SIBN exceeded the US Medical Equipment industry which returned 3.2% over the past year.
Return vs Market: SIBN exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| SIBN volatility | |
|---|---|
| SIBN Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SIBN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SIBN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 349 | Laura Francis | si-bone.com |
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products.
SI-BONE, Inc. Fundamentals Summary
| SIBN fundamental statistics | |
|---|---|
| Market cap | US$675.59m |
| Earnings (TTM) | -US$23.76m |
| Revenue (TTM) | US$185.26m |
Is SIBN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIBN income statement (TTM) | |
|---|---|
| Revenue | US$185.26m |
| Cost of Revenue | US$38.08m |
| Gross Profit | US$147.18m |
| Other Expenses | US$170.95m |
| Earnings | -US$23.76m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 10, 2025
| Earnings per share (EPS) | -0.55 |
| Gross Margin | 79.45% |
| Net Profit Margin | -12.83% |
| Debt/Equity Ratio | 20.8% |
How did SIBN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 13:12 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SI-BONE, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |